The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

Prothena Corporation’s Phase III AFFIRM-AL trial of birtamimab in individuals with amyloid light-chain (AL) amyloidosis misses its primary endpoint of time to all-cause death, leading to the ...

Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being ...

Alnylam Pharmaceuticals, Inc. ALNY announced that the European Commission (EC) has approved a label expansion of its RNAi ...

Aortic valve narrowing (aortic stenosis) with concomitant cardiac amyloidosis is a severe heart disease of old age that is ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

It is important for the nurse to assess the extent of kidney involvement in amyloidosis and the development of the nephrotic syndrome. The nephrotic syndrome is suspected when there are high ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.

Prothena Corporation plc (NASDAQ:PRTA) released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday. AL (amyloid light-chain) amyloidosis is ...

− First and Only RNAi Therapeutic Approved by the European Commission for the Treatment of Wild-Type or Hereditary ATTR Amyloidosis with Cardiomyopathy – − Novel RNAi Mechanism Delivers ...